LivaNovaLIVN
About: UK-based LivaNova was born of a combination between Cyberonics in the us and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the us market, another 21% from Europe, and the remainder from the rest of the world.
Employees: 2,900
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
361% more call options, than puts
Call options by funds: $3.35M | Put options by funds: $727K
58% more repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 67
50% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 3 (+1) [Q4]
45% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 33
3.85% more ownership
Funds ownership: 96.39% [Q3] → 100.24% (+3.85%) [Q4]
3% more funds holding
Funds holding: 242 [Q3] → 250 (+8) [Q4]
8% less capital invested
Capital invested by funds: $2.74B [Q3] → $2.52B (-$221M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target | 58%upside $75 | Buy Reiterated | 28 Jan 2025 |
Financial journalist opinion
